BioCentury
ARTICLE | Clinical News

Samumed unveils MOA for Wnt inhibitor OA therapy

February 8, 2019 5:29 AM UTC

Samumed LLC (San Diego, Calif.) reported preclinical data showing that its small molecule Wnt pathway inhibitor osteoarthritis therapy, SM04690, functions through CLK-2 and DYRK1A inhibition. Data were presented at the Orthopaedic Research Society meeting in Austin.

In vitro, SM04690 inhibited the Wnt pathway with an EC50 value of 11 nm. In a kinome screen, SM04690 inhibited CLK-2 and DYRK1A with EC50 values of 5.8 and 26.9 nM, respectively...